Free Trial
Sadia Rahman

Sadia Rahman Analyst Performance

Vice President, Biopharma Equity Research at Wells Fargo & Company

Sadia Rahman is a stock analyst at Wells Fargo & Company focused in the medical sector, covering 3 publicly traded companies. Over the past year, Sadia Rahman has issued 4 stock ratings, including and buy recommendations. While full access to Sadia Rahman's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Sadia Rahman's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
4 Last 0 Years
Buy Recommendations
100.00% 4 Buy Ratings
Companies Covered
3 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy100.0%4 ratings
Hold0.0%0 ratings
Sell0.0%0 ratings

the majority (100.0%) have been Buy recommendations.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
3 companies

Sadia Rahman, an analyst at Wells Fargo & Company, currently covers 3 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
2 companies
66.7%
Manufacturing
1 company
33.3%

Sadia Rahman of Wells Fargo & Company specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
2 companies
66.7%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
1 company
33.3%

Sadia Rahman's Ratings History at Wells Fargo & Company

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
3/19/2026Initiated Coverage$13.00$30.00Overweight
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
3/19/2026Initiated Coverage$78.86$135.00Overweight
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
12/4/2025Initiated Coverage$41.49$55.00Overweight
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
12/4/2025Initiated Coverage$41.46$55.00Overweight